Go ahead, have a drink. Science proves that it won’t give you a migraine.

December 18, 2022

Holidays are again upon us. There are many reasons why people experience more migraines this time of year. Family drama, all the delicious unhealthy food, and alcohol. A report just published in the journal Headache brings some good news. Scientists proved that alcohol does not trigger migraines.

The researchers evaluated the digital diaries of 493 migraine sufferers who reported drinking alcohol. They used sophisticated statistical analysis including standard deviations, Bayesian statistics, Markov Chain Monte Carlo simulations, and the like, to show that there was no correlation between drinking alcohol and developing a migraine the next day.

If you still insist that alcohol gives you migraines, to paraphrase Groucho Marx, who are you going to believe, the scientists or your own lying eyes?

Another amusing paper comparing red wine with vodka as a trigger of migraines was published years ago by British researchers in The Lancet

Migraine patients who believed that red wine but not vodka triggered their attacks were challenged either with red wine or vodka. It was a blinded study – patients were not told what they were drinking. Vodka was diluted to equivalent alcohol content, and both were “consumed cold out of dark bottles to disguise colour and flavour”. And indeed, only wine triggered a migraine attack. A group of French doctors responded to this study in a letter to the editor. They stated that the only thing this study proved was that the Brits can’t tell wine from vodka.

Written by
Alexander Mauskop, MD
Continue reading
August 8, 2026
Sugar is bad for your brain, even before you are born.
Sugar consumed in the first two years of life increases the risk of dementia.
Read article
August 6, 2026
Research
An Old Medicine that Could Make Brain Stimulation Work Better for Depression and Other Neurological Conditions
A 2022 clinical trial from the University of Calgary found that adding low‑dose D‑cycloserine (DCS), a partial NMDA‑receptor agonist, to intermittent theta‑burst stimulation (iTBS) significantly increased response and remission rates in depression without serious side effects. Early follow‑up data suggest that timing, dose, and drug levels matter, and raise the possibility that this DCS‑TMS approach could eventually be applied to other neurological conditions—such as migraine, postconcussion syndrome, brain fog, and long COVID
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe